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Aortic aneurysms in Loeys-Dietz syndrome —
a tale of two pathways?
Frank Davis, Debra L. Rateri, and Alan Daugherty
Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky, USA.

Loeys-Dietz syndrome (LDS) is a connective tissue disorder that is characterized by skeletal abnormalities, craniofacial malformations, and a
high predisposition for aortic aneurysm. In this issue of the JCI, Gallo et
al. developed transgenic mouse strains harboring missense mutations in
the genes encoding type I or II TGF-β receptors. These mice exhibited several LDS-associated phenotypes. Despite being functionally defective, the
mutated receptors enhanced TGF-β signaling in vivo, inferred by detection
of increased levels of phosphorylated Smad2. Aortic aneurysms in these
LDS mice were ablated by treatment with the Ang II type 1 (AT1) receptor
antagonist losartan. The results from this study will foster further interest
into the potential therapeutic implications of AT1 receptor antagonists.
TGF-β and Ang II pathways in
thoracic aortic aneurysmal formation
Aneurysms that present in the thoracic
aorta have a wide range of syndromic and
nonsyndromic associations (1). Marfan
syndrome is one of the most researched
syndromic associations and is attributed to
a wide spectrum of mutations in fibrillin-1,
which have been proposed to enhance the
bioavailability of TGF-β (2). The understanding of the role of TGF-β in the etiology of thoracic aortic aneurysms (TAAs)
moved forward with the development of
mice that expressed the C1039G mutant of
fibrillin-1. These mice, colloquially referred
to the “Marfan mouse,” exhibit many
Marfan-associated phenotypes, including
a predisposition for aortic aneurysms.
TGF-β–neutralizing antibody administration to Marfan mice prevented the characteristic media elastin disruption and aortic root expansion (3). Furthermore, the
neutralizing antibody decreased canonical
TGF-β signaling in aortic smooth muscle
cells, as defined by immunostaining of tissues for the phosphorylated form of Smad2
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(pSmad2). Another seminal discovery in
the Marfan mouse was that administration
of losartan, the initial member of the Ang
II type 1 receptor (AT1R) blocker (ARB)
class, ablated ascending aortic dilation.
Subsequent studies in this mouse model
have demonstrated that losartan-associated reductions in ascending aortic expansion are attributable to inhibition of the
ERK pathway (4, 5). These groundbreaking studies in mice have assisted in development of multiple clinical trials that are
evaluating efficacy of AT1R antagonism
in thoracic aortic dilation of patients with
Marfan syndrome (6). Although these studies shed light on the interactions between
TGF-β and AT1R signaling in TAA development, the specific mechanism of these
interactions has not been elucidated (7).
TGF-β was further implicated in the
development of aortic aneurysms following the discovery of mutations in the
genes encoding TGF-β receptors in individuals afflicted with a clinical syndrome
that has similarities to Marfan syndrome.
This condition was subsequently termed
Loeys-Dietz syndrome (LDS). Patients
afflicted with LDS have a more aggressive
form of ascending aortic dilation compared with those with Marfan syndrome
(8). Dilation of the aortic root is detected

very early, with documented aortic dissections occurring in patients with LDS
as young as 3 months of age (9). Unlike
Marfan syndrome, the vascular pathologies associated with LDS are more diffuse
in location, as these aneurysms occur in
other aortic regions and several vascular
beds (10). The genetic basis of LDS is the
presence of mutations in the genes encoding either type I or type II TGF-β receptors
(11). TGF-β receptors function as multimers of both subtypes; therefore, clinical
presentations are similar when defects
are present in either receptor subtype.
Although the TGF-β receptor mutations
result in impaired function, detection of
enhanced Smad2 or Smad3 phosphorylation in surgical samples implies that TGF-β
signaling is actually increased in patients
with LDS (11). The involvement of TGF-β
signaling in LDS development parallels the
mechanisms of TAAs in Marfan syndrome.
Unlike Marfan syndrome, there is a paucity
of information on a role for Ang II in LDS.
TGF-β receptor mutations promote
aortic aneurysms in LDS
mouse models
In this issue of the JCI, Gallo et al. (12)
generated an array of mouse models with
TGF-β receptor dysfunction. These mouse
models included mice with haploinsufficiency of either TGF-β receptor (Tgfbr1+/–
or Tgfbr2+/– mice), knockin of LDS-associated alleles (Tgfbr1 M318R or Tgfbr2 G357W
mice), and transgenic overexpression of
the Tgfbr2 G357W mutant. Haploinsufficiency of either receptor subtype did not
produce vascular pathologies; however,
heterogenous knockin of Tgfbr1 M318R or
Tgfbr2G357W mutations or transgenic overexpression of mutated Tgfbr2G357W led to
severe aortic pathologies. These included
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Figure 1
Convergence of the TGF-β and Ang II signaling pathways is implicated in TAA. Missense mutations in either the TGF-β receptor (TGFR) type 1 or 2 subtypes, specifically Tgfbr2G357W and
Tgfbr1M318R, lead to increased abundance of pSmad2 and pERK in mouse models of LDS. The
increase in these activated proteins correlates with increased elastin fragmentation and aortic
root dilation. Administration of losartan, an ARB, suppressed Smad2 and ERK phosphorylation
and prevented aortic dilation. However, important mechanistic questions remain. (i) Why does
administration of a TGF-β–neutralizing antibody (1D11 Nab) fail to reduce aortic root dilation?
(ii) How does defective TGF-β signaling augment AT1R stimulation? (iii) How do functionally
defective TGF-β receptors promote increased phosphorylation of Smad2 and ERK? (iv) What
are the downstream targets of pSmad2 and pERK that cause elastin fragmentation and subsequent aortic aneurysm?

aortic root expansion and rupture and
increased tortuosity of the thoracic aorta.
Overall, mice expressing mutant forms of
TGF-β receptors exhibited many features
of LDS, which permitted mechanistic
studies of this disease.
Initially, mechanistic insight was gleaned
from cultured smooth muscle cells harvested from aortic roots of wild-type,
Tgfbr2+/–, Tgfbr2G357W knockin, and transgenic mice. As expected, stimulation with
TGF-β promoted less pSmad2 abundance
in cells expressing mutant receptors compared with controls. The lack of TGF-β
responsiveness was not attributable to
differences in cell surface expression of
the receptors. Vascular smooth muscle
cells harvested from patients with LDS
also demonstrated partial attenuation
of TGF-β–induced Smad2 phosphorylation. Receptor deficiencies did not lead to
marked upregulation of TGF-β secretion
in mouse cells, and only TGF-β2 secretion
was increased in cells from patients with
LDS. The results from these cell culture
80

experiments corroborated previous studies
that demonstrated decreased TGF-β signaling as a result of LDS-associated TGF-β
receptor mutations (1).
Subsequent studies by Gallo et al. determined the fidelity of extrapolating these
cell culture studies to the intact mouse (12).
Western blot analysis of aortic root tissue
from mice harboring either the Tgfbr1M318R
or Tgfbr2G357W mutation revealed that there
was no alteration in pSmad2 abundance
within the 24-week interval in which aortic
expansion was measured. Given that analysis of whole tissue homogenates might
obfuscate regional pSmad2 changes, Gallo
et al. (12) performed immunostaining to
visualize pSmad2 in aortic roots. While this
technique does not easily lend itself to quantitative comparisons, greater immunofluorescent signals were observed in aortic media
and adventitial tissues from Tgfbr2G357W
knockin mice compared with controls. The
explanation as to why these data seemingly
contradict the cell culture studies is certainly a matter of debate and intrigue. One

potential issue is the promiscuity of Smad2
phosphorylation, which is not exclusively a
result of TGF-β signaling. Therefore, the use
of Smad2 phosphorylation as an indicator
of TGF-β pathway activation could compromise data interpretation (13). Another
intriguing aspect of the Gallo et al. study
was that administration of a TGF-β–neutralizing antibody failed to prevent aortic root
dilation, unlike the efficacy of this antibody
treatment that has been demonstrated in the
Marfan mouse (3).
In contrast to TGF-β neutralization,
Gallo et al. (12) provided convincing
evidence that losartan administration
ablated aortic pathology and expansion. Similar to the Marfan mouse, the
decreased pathology was not mimicked
by administration of a β-adrenoceptor
antagonist (3). While losartan is primarily
defined as an AT1R antagonist, its metabolites do have a potential range of other
activities (14). Therefore, evaluation of
other ARBs would assist in determining
whether losartan-associated effects are
due specifically to AT1R antagonism.
Mechanism of TGF-β and Ang II
interactions in TAA development
The authors conclude that aortic pathologies are generated by Ang II augmentation of TGF-β signaling (Figure 1). Indeed,
Ang II stimulates TGF-β signaling by
promoting secretion of TGF-β isoforms
from vascular smooth muscle cells (15).
Conversely, TGF-β signaling in vascular
smooth muscle cells downregulates AT1R
expression (16). The specific mechanisms
by which defective TGF-β receptors lead
to augmented AT1R stimulation and generation of aortic pathologies in LDS is
still a quandary. This issue is further complicated by evidence that suggests that
TGF-β promotes ascending aortic dilation through a combination of AT1R-dependent and -independent pathways (17).
Clearly, additional studies are warranted
to further elucidate the pathways that
promote aortic aneurysm.
Therapeutic implications
Overall, the findings of Gallo et al. (12)
provide important insight into the pathogenesis of aortic aneurysms in LDS. The
authors demonstrated that a missense
mutation in a single allele within either of
the genes encoding TGF-β receptor type 1
or 2 is sufficient to recapitulate LDS phenotypes in mice. In addition, these studies provide rationale for considering the
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application of AT1R antagonism as a therapy for patients with LDS. There is both
retrospective and evolving prospective evidence that AT1R antagonism may be beneficial to patients with Marfan syndrome (6,
18, 19). Together, the findings in patients
with Marfan syndrome and the results
from the Gallo et al. study (12) indicate
that patients with LDS may potentially
benefit from AT1R antagonism. Losartan
has been the ARB of choice in most ongoing trials; however, the use of an ARB with
a more favorable pharmacokinetic profile
and longer half-life may enhance the protective effects against TAAs. The availability of the LDS mouse described by Gallo
et al. (12) provides a model to determine
the relative efficacies of this class of drugs
before application to humans.
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Toward postnatal reversal
of ocular congenital malformations
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Aniridia is a panocular disorder that severely affects vision in early life. Most
cases are caused by dominantly inherited mutations or deletions of the PAX6
gene, which encodes a transcription factor that is essential for the development of the eye and the central nervous system. In this issue of the JCI, Gregory-Evans and colleagues demonstrate that early postnatal topical administration of an ataluren-based formulation reverses congenital malformations
in the postnatal mouse eye, providing evidence that manipulation of PAX6
after birth may lead to corrective tissue remodeling. These findings offer
hope that ataluren administration could be a therapeutic paradigm applicable to some major congenital eye defects.

cer are the result of such mutations (1, 2).
These mutations are referred to as nonsense
mutations, premature stop mutations, or
premature termination codons (PTCs).
Given that PTCs often result in a complete
loss of protein function, the associated
diseases usually manifest as severe phenotypes. Examples of PTC-associated diseases
include CF, Duchenne muscular dystrophy
(DMD), and aniridia, among others.

Mutations that inactivate gene function by
promoting premature translational termination cause a large number of human diseases. It is thought that at least one-third of
all genetic diseases and many types of can-

Aniridia, a panocular disorder
Aniridia is a rare eye disease with an estimated prevalence of approximately 1 in
40,000 to 1 in 100,000 individuals. It is
present at birth and characterized by a total
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